ReviewCurrent oncology reports2022

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.

Xiao-Yin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.